# Parkinson's Agents

This is a subcategory of Central Nervous System (CNS) Agents.

## Formulary

### Preferred

| Preferred          |
| :----------------- |
| Amantadine         |
| Carbidopa          |
| Carbidopa/Levodopa |
| Entacapone         |
| Pramipexole        |
| Ropinirole         |
| Selegiline         |

### Non-Preferred

| Non-Preferred                      |
| :--------------------------------- |
| Apokyn                             |
| Carbidopa/Levodopa Dispersible Tab |
| Carbidopa/Levodopa/Entacapone      |
| Gocovri                            |
| Inbrija                            |
| Kynmobi                            |
| Neupro                             |
| Nourianz                           |
| Ongentys                           |
| Osmolex ER                         |
| Pramipexole ER                     |
| Rasagiline                         |
| Ropinirole ER                      |
| Rytary                             |
| Tolcapone                          |
| Xadago                             |
| Zelapar                            |

## Length of Authorizations

365 Days

## Prior Authorization Criteria

Is there any reason the patient cannot be changed to a medication not requiring prior approval? Acceptable reasons include:

-   Allergy to medications not requiring prior approval
-   Contraindication to or drug interaction with medications not requiring prior approval
-   History of unacceptable/toxic side effects to medications not requiring prior approval

## Additional Information

The requested medication may be approved if both of the following are true:

1.  If there has been a therapeutic failure to no less than a **30-day** trial of at least **one** medication not requiring prior approval
2.  The requested medication’s corresponding generic (if covered by the state) has been attempted and failed or is contraindicated.
3.  Neupro may be approved if the patient is unable to swallow.
4.  Requests for Apokyn, Inbrija, Kynmobi and Nourianz must have documentation of a trial of at least one other medication for the treatment of “off episodes” (dopamine agonist, COMT inhibitor, or MAO-B inhibitor).

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_Criteria_APPROVED.pdf#page=41)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20221001_UPDL_APPROVED_.pdf#page=17)
